Sotac Pharmaceuticals IPO is a book build IPO listing on NSE EMERGE exchange. The company is based in Ahmedabad and caters to Pharmaceutical sector. Beeline Capital Advisors Private is the merchant banker of Sotac Pharmaceuticals IPO. It is a SME IPO which filed its Draft Red Herring Prospectus (DRHP) on 7th February 2023.
Sotac Pharmaceuticals IPO posted revenues of Rs 79.90 crores and PAT of Rs 0.94 crores in FY23 on annualised basis.Financial results of Sotac Pharmaceuticals IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
Sotac Pharmaceuticals IPO PAT Margin is 1.16%, ROCE (Return on Capital Employed) is 42.50% as per latest financial. The below table shows Sotac Pharmaceuticals IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
The market Capitalisation of Sotac Pharmaceuticals IPO is Rs 122.66 crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Sotac Pharmaceuticals IPO prospectus highlights an Return on Equity (ROE) of 15%, Return on Assets (ROA) of 12%, and an EBITDA Margin of 18%, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Sotac Pharmaceuticals IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Sotac Pharmaceuticals IPO is ₹122.66 Cr, based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Sotac Pharmaceuticals IPO has a Price-to-Earnings (PE) ratio of 132.14 X, indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Sotac Pharmaceuticals IPO reported revenue of ₹79.90 Cr in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Sotac Pharmaceuticals IPO provide insights into sales growth, market demand, and business scalability.
Sotac Pharmaceuticals recorded an EBITDA of ₹ 7.34 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Sotac Pharmaceuticals Profit After Tax (PAT) is ₹0.92 Cr, reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Sotac Pharmaceuticals operates in Pharmaceutical and Manufacturing Of Pharmaceutical Products. The Issue is listed on NSE EMERGE in Apr, 2023. Sotac Pharmaceuticals IPO size was 33.30 with Issue price of 111.00 .
Merchant Banker(s) of Sotac Pharmaceuticals IPO: Beeline Capital Advisors Private Limited
Sotac Pharmaceuticals IPO subscription was 1.60 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Sotac Pharmaceuticals IPO listed at a listing price of 115.00 against the offer price of 111.00.
The current market price of Sotac Pharmaceuticals is 118.70.
Why Us?